Tezepelumab for asthma

The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can pro- mote and regulate inflammatory processes through the production of cytokines, namely interleukin (IL) -25, IL -33 and thymic stromal lymphopoietin (TSLP), known as "alarmins". TSLP, in particular, has been extensively studied as a possible therapeutic target in patients with severe asthma because it is involved in the infla- mmatory processes of both type 2 -high and type 2 -low inflammation. In this regard, tezepelumab (AMG-157/ MEDI-9929), a TSLP-targeted first-in -class fully human monoclonal antibody, has been shown in phase II and III studies to be effective and safe in treating patients with severe asthma, regardless of the underlying endo- type or phenotype and irrespective of baseline bio- markers, such as blood eosinophil count and fraction of exhaled nitric oxide. Here, we provide a comprehen- sive review of TSLP function in airway inflammatory processes, the clinical development of tezepelumab for severe asthma as well as its possible future indications.